Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 243

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

A phase 2 clinical trial of metformin as a treatment for non‐diabetic paediatric non‐alcoholic steatohepatitis

Open access
Schwimmer, J. B., Middleton, M. S., Deutsch, R., Lavine, J. E.·2005·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background : Children with non‐alcoholic steatohepatitis are insulin‐resistant and metformin has been proposed as a potential therapy. However, paediatric safety and efficacy data are absent. Aim : To test the hypothesis that metformin therapy will safely improve markers of liver disease in paediatric non‐alcoholic steatohepatitis. Methods : Single‐arm open‐label pilot study of metformin 500 mg twice daily for 24 weeks in non‐diabetic children with biopsy‐proven non‐alcoholic steatohepatitis. Results : Ten obese children (mean body mass index 30.4) enrolled and completed the trial. Mean alanine aminotransferase and aspartate aminotransferase (AST) improved significantly (P < 0.01) from baseline (184, 114 U/L) to end of treatment (98, 68 U/L). Alanine aminotransferase normalized in 40% and AST normalized in 50% of subjects. Children demonstrated significant improvements in liver fat measured by magnetic resonance spectroscopy (30–23%, P < 0.01); insulin sensitivity measured by quantitative insulin sensitivity check index (0.294–0.310, P < 0.05); and quality of life measured by pediatric quality of life inventory 4.0 (69–81, P < 0.01). Conclusion : Open‐label treatment with metformin for 24 weeks was notable for improvement in liver chemistry, liver fat, insulin sensitivity and quality of life. A large randomized‐controlled trial is needed to definitively determine the efficacy of metformin for paediatric non‐alcoholic steatohepatitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2005.02420.x

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 243

Metadata

Authors
Schwimmer, J. B., Middleton, M. S., Deutsch, R., & Lavine, J. E.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2005-03-24
Volume
21
Issue
7
Pages
871-879
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1979959518
Cited by
243
References
13
FWCI
17.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 2 clinical trial of metformin as a treatment for non‐diabetic paediatric non‐alcoholic steatohepatitis. https://app.cochat.ai/papers/10.1111/j.1365-2036.2005.02420.x
The paper
Schwimmer, J. B., Middleton, M. S., Deutsch, R., & Lavine, J. E. (2005). A phase 2 clinical trial of metformin as a treatment for non‐diabetic paediatric non‐alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2005.02420.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.